Skip to main content
Erschienen in: Clinical & Experimental Metastasis 1/2015

01.01.2015 | Research Paper

Bone metastases in gastrointestinal cancer

verfasst von: Fabienne Portales, Simon Thézenas, Emmanuelle Samalin, Eric Assenat, Thibault Mazard, Marc Ychou

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Colorectal (CRC) and gastroesophageal (GEC) cancers unusually spread to the bone. However, bone metastases (BM) are responsible for skeletal-related events (SREs) associated with an altered quality of life. Aiming to describe the characteristics and prognostic influence of BM from gastro-intestinal cancers, we performed a retrospective analysis of prospectively collected data in patients treated in our institution (1996–2006). 189 patients (5.5 %) developed BM: 79 with GEC and 110 with CRC. 57 patients had bone-exclusive metastases. In univariate analyses, the median time to BM occurrence was correlated with the primary tumour (PT) localisation, surgery, histology and TNM staging. However, in multivariate analyses, the occurrence delay was significantly shorter only for patients with GEC (HR 2.1), N1–2 status (HR 1.9), M1 status (HR 2.4), and epidermoid carcinoma (HR 6.0). Pain was the most frequent clinical sign leading to BM diagnosis (77.2 %). SRE occurred in 55 % of patients. Median overall survivals (OSs) of patients with CRC and GEC were 9.4 months [95 % confidence interval (95 % CI) 6.4–11.1] and 3.4 months (95 % CI 2.5–9.0), respectively. In univariate analyses, OS was correlated with PT surgery and NM staging, and the number of BM. In multivariate analyses, only the PT surgery and the number of BM remained correlated with OS. Our results suggest that there may be a subset of patients associated with a quicker development of BM. Given their higher risk of SRE, they could benefit from an early screening, calling for further prospective studies encompassing patients with and without BM.
Fußnoten
1
IFL (irinotecan, 5-fluorouracile and leucovorin).
 
2
IROX (irinotecan and oxaliplatin).
 
3
FOLFOX (5-fluorouracile, oxaliplatin and leucovorin).
 
Literatur
1.
Zurück zum Zitat Milosavljevic T, Kostic-Milosavljevic M, Jovanovic I, Krstic M (2010) Gastrointestinal and liver tumours and public health in Europe. Eur Rev Med Pharmacol Sci 14:259–262PubMed Milosavljevic T, Kostic-Milosavljevic M, Jovanovic I, Krstic M (2010) Gastrointestinal and liver tumours and public health in Europe. Eur Rev Med Pharmacol Sci 14:259–262PubMed
5.
Zurück zum Zitat Sundermeyer ML, Meropol NJ, Rogatko A et al (2005) Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer 5:108–113PubMedCrossRef Sundermeyer ML, Meropol NJ, Rogatko A et al (2005) Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer 5:108–113PubMedCrossRef
6.
10.
15.
16.
Zurück zum Zitat Besbeas S, Stearns MW Jr (1978) Osseous metastases from carcinomas of the colon and rectum. Dis Colon Rectum 21:266–268PubMedCrossRef Besbeas S, Stearns MW Jr (1978) Osseous metastases from carcinomas of the colon and rectum. Dis Colon Rectum 21:266–268PubMedCrossRef
18.
Zurück zum Zitat Katoh M, Unakami M, Hara M, Fukuchi S (1995) Bone metastasis from colorectal cancer in autopsy cases. J Gastroenterol 30:615–618PubMedCrossRef Katoh M, Unakami M, Hara M, Fukuchi S (1995) Bone metastasis from colorectal cancer in autopsy cases. J Gastroenterol 30:615–618PubMedCrossRef
21.
24.
Zurück zum Zitat Stopeck AT, Lipton A, Body J-J et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132–5139. doi:10.1200/JCO.2010.29.7101 PubMedCrossRef Stopeck AT, Lipton A, Body J-J et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132–5139. doi:10.​1200/​JCO.​2010.​29.​7101 PubMedCrossRef
25.
Zurück zum Zitat Saad F, Gleason DM, Murray R et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879–882PubMedCrossRef Saad F, Gleason DM, Murray R et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879–882PubMedCrossRef
26.
Zurück zum Zitat Rosen LS, Gordon D, Tchekmedyian NS et al (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 100:2613–2621. doi:10.1002/cncr.20308 PubMedCrossRef Rosen LS, Gordon D, Tchekmedyian NS et al (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 100:2613–2621. doi:10.​1002/​cncr.​20308 PubMedCrossRef
27.
28.
Zurück zum Zitat Janni W, Vogl FD, Wiedswang G et al (2011) Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse—a European pooled analysis. Clin Cancer Res 17:2967–2976. doi:10.1158/1078-0432.CCR-10-2515 PubMedCrossRef Janni W, Vogl FD, Wiedswang G et al (2011) Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse—a European pooled analysis. Clin Cancer Res 17:2967–2976. doi:10.​1158/​1078-0432.​CCR-10-2515 PubMedCrossRef
31.
34.
Zurück zum Zitat Goldberg RM, Sargent DJ, Morton RF et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–30. doi:10.1200/JCO.2004.09.046 PubMedCrossRef Goldberg RM, Sargent DJ, Morton RF et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–30. doi:10.​1200/​JCO.​2004.​09.​046 PubMedCrossRef
35.
Zurück zum Zitat Henry DH, Costa L, Goldwasser F et al (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125–1132. doi:10.1200/JCO.2010.31.3304 PubMedCrossRef Henry DH, Costa L, Goldwasser F et al (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125–1132. doi:10.​1200/​JCO.​2010.​31.​3304 PubMedCrossRef
Metadaten
Titel
Bone metastases in gastrointestinal cancer
verfasst von
Fabienne Portales
Simon Thézenas
Emmanuelle Samalin
Eric Assenat
Thibault Mazard
Marc Ychou
Publikationsdatum
01.01.2015
Verlag
Springer Netherlands
Erschienen in
Clinical & Experimental Metastasis / Ausgabe 1/2015
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-014-9686-x

Weitere Artikel der Ausgabe 1/2015

Clinical & Experimental Metastasis 1/2015 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.